BioVersys Works to Bring Antibiotic Resistance to an End

Authors

  • Marcel Tigges BioVersys AG, Hochbergerstrasse 60c, c/o Technologiepark, CH-4057 Basel, Switzerland. info@bioversys.com
  • Marc Gitzinger BioVersys AG, Hochbergerstrasse 60c, c/o Technologiepark, CH-4057 Basel, Switzerland

DOI:

https://doi.org/10.2533/chimia.2014.888

Keywords:

Antibiotic resistance, Bioversys, Life science start-up, Nosocomial infections, Tric, Tuberculosis

Abstract

BioVersys, founded in 2008, is working on bringing a technology for screening and for the development of 'transcriptional regulator inhibiting compounds' (TRICs) to patients in order to overcome antibiotic resistance. The co-founders share their view on what makes successful scientists pursue a career as start-up entrepreneurs rather than a classic academic career. They describe the history and milestones of their company, and how their everyday work differs from that of peers in an academic or industrial research setting.
CHIMIA Vol. 68 No. 12 (2014): Life Science START-UPS in Switzerland

Downloads

Published

2014-12-17

Issue

Vol. 68 No. 12 (2014): Life Science START-UPS in Switzerland

Section

Scientific Articles

License

Copyright (c) 2014 Swiss Chemical Society

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

[1]
M. Tigges, M. Gitzinger, Chimia 2014, 68, 888, DOI: 10.2533/chimia.2014.888.